Biogen Idec (NASDAQ: BIIB) announced new data that continue to support TECFIDERA® (dimethyl fumarate) as an effective, long-term treatment for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Baird Remains Buyers of Biogen (BIIB) Despite Kyle Bass Tecfidera ChallengeApril 22, 2015 3:50 PM Kyle Bass files challenge to Biogen (BIIB) patent on Tecfidera - BloombergApril 22, 2015 11:13 AM TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS PatientsApril 20, 2015 7:30 AM RBC Comments on Biogen's (BIIB) Alzheimer's Late-BreakerApril 17, 2015 11:42 AM Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia DayApril 16, 2015 9:00 AM